Many factors that affect CYP activities, including genetic polymorphisms, diseases, medications, certain foods, physiological conditions, and smoking, can alter pharmacokinetic profiles which are affecting chemotherapeutic efficacy in glioblastoma tumor cells [27]. The gene discussed is PPIG; the disease is neoplasm.